Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract

Journal of Urology

Volumn 156, Issue 4, 1996, Pages 1280-1285

  Carpinito, Gennaro A ^a   Stadler, Walter M ^a   Briggman, Joseph V ^a   Chodak, Gerald W ^a   Church, Paul A ^a   Lamm, Donald L ^a   Lange, Paul H ^a   Messing, Edward M ^a   Pasciak, Robert M ^a   Reservitz, George B ^a   Ross, Robert N ^a   Rukstalis, Daniel B ^a   Sarosdy, Michael F ^a   Soloway, Mark S ^a   Thiel, Robert P ^a   Vogelzang, Nicholas ^a   Hayden, Cheryl L ^a  

^a NONE

Author keywords

bladder; bladder neoplasms; carcinoma; nuclear matrix; nuclear proteins; transitional cell

Indexed keywords

NUCLEAR PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; URINARY NUCLEAR MATRIX PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ISOLATION; REFERENCE VALUE; TRANSITIONAL CELL CARCINOMA;

EID: 9544247720     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65569-1     Document Type: Article

References (18)

1. American Cancer Society: Cancer Facts & Figures-1995. Atlanta: American Cancer Society, 1995.
2. Boring, C. C., Squires, T. S. and Tong, T.: Cancer statistics, 1995. CA, 45: 8, 1995.
3. Paulson, D. F., Ferez, C. and Anderson, T.: Genito-urinary malignancies. In: Cancer. Principles and Practices of Oncology. Edited by V. T. DeVita, Jr., S. Hellman and S. A. Rosenberg. Philadelphia: J. B. Lippincott Co., 1982.
4. Raghaven, D., Shipley, W. U., Garnick, M. B., Russell, P. J. and Richie, J. P.: Biology and management of bladder cancer. New Engl. J. Med., 322: 1129, 1990.
5. Berezney, R. and Coffey, D. S.: Identification of a nuclear protein matrix. Biochem. Biophys. Res. Comm., 60: 1410, 1974.
6. Pardoll, D. M., Vogelstein, B. and Coffey, D. S.: A fixed site of DNA replication in eucaryotic cells. Cell, 19: 527, 1980.
7. Zeitlin, S., Parent, A., Silverstein, S. and Efstratiadis, A.: PremRNA splicing and the nuclear matrix. Molec. Cell. Biol., 7: 111, 1987.
8. Kumara-Siri, M. H., Shapiro, L. E. and Surks, M. I.: Association of the 3,5,3′-triiodo-L-thryonine nuclear receptor with the nuclear matrix of cultured growth hormone-producing rat pituitary tumor cells (GC cells). J. Biol. Chem., 261: 2844, 1986.
9. Nakayasu, H. and Berezney, R.: Mapping replicational sites in the eucaryotic cell nucleus. J. Cell. Biol., 108: 1, 1989.
10. Keesee, S., Briggman, J. B., Thill, G. and Wu, Y. J.: Utilization of nuclear matrix proteins for cancer diagnosis. In: Critical Review in Eukaryotic Gene Expression. Edited by Gary Stein, vol. 6, pp. 189-214, 1996.
11. Briggman, J. V., Roos, R., Merrifield, S. A. and Pasciak, R. E.: NMP22 antigen characterization. Unpublished data.
12. Yang, C. H., Lambie, E. J. and Snyder, M.: NuMA: an unusually long coiled-coil related protein in the mammalian nucleus. J. Cell. Biol., 116: 1303, 1992.
13. Compton, D. A. and Cleveland, D. W.: NuMA is required for the proper completion of mitosis. J. Cell. Biol., 120: 947, 1993.
14. Soloway, M. S., Briggman, J. V., Carpinito, G. A., Chodak, G. W., Church, P. A., Lamm, D. L., Lange, P., Messing, E. M., Pasciak, R. M., Reservitz, G. B., Rukstalis, D. B., Sarosdy, M. F., Stadler, W. M., Thiel, R. P. and Hayden, C. L.: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J. Urol., 156: 363, 1996.
15. DeVere White, R. W., Meyers, F. J. and Deithch, A. D.: DNA flow cytometry in transitional cell carcinoma of the bladder. Probl. Urol., 2: 436, 1988.
16. Bonner, R. B., Hemstreet, G. P., III, Fradet, Y., Rao, J. Y., Min, K. W. and Hurst, R. E.: Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells. Cancer, 72: 2461, 1993.
17. Golijanin, D., Sherman, Y., Shapiro, A. and Pode, D.: Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine. Urology, 46: 173, 1995.
18. Sarodsy, M. F., deVere White, R. W., Soloway, M. S., Sheinfeld, J., Hudson, M. A., Schellhammer, P. F., Jarowenko, M. V., Adams, G. and Blumenstein, B. A.: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J. Urol., 154: 379, 1995.